The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

In May 2025, Praxis provided an update on the EMBOLD cohort 1 study group in SCN2A and SCN8A DEEs, showing patients in the open-label extension up to 11 months had a ~90% reduction in seizures from ...